Loading...
XNAS
SNDX
Market cap2.09bUSD
Jul 10, Last price  
23.61USD
1D
1.14%
1Q
1.64%
Jan 2017
246.44%
IPO
109.62%
Name

Syndax Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:SNDX chart
P/E
—
P/S
12.14
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.96%
Rev. gr., 5y
157.68%
Revenues
172m
+627.84%
0000627,0001,220,0002,108,0001,517,0001,517,0001,517,000139,709,0000023,680,000172,352,000
Net income
-285m
L-10.46%
-13,089,000-9,965,000-14,171,000-19,828,000-24,119,000-44,472,000-60,802,000-73,961,000-55,955,000-73,069,00024,926,000-149,338,000-209,360,000-318,758,000-285,422,000
CFO
-323m
L+17.49%
-10,022,000-9,284,000-7,295,000-14,393,000-2,428,000-35,157,000-47,371,000-68,531,000-50,612,000-71,260,00029,131,000-133,675,000-160,601,000-274,903,000-322,980,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
URL
https://syndax.com/
IPO date
Mar 03, 2016
Employees
107
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT